Transkaryotic Therapies said that a late-stage trial of its drug for Hunter syndrome demonstrated a statistically significant improvement for patients. The company says the results clears the way for an expected license application by the end of the year in Europe and the US. The news boosted shares of Shire, which is buying Transkaryotic. "Patients with Hunter syndrome are now one step nearer to being able to obtain treatment for this debilitating and life threatening condition with the release of this new trial data from TKT," said Shire chief executive, Matthew Emmens.
- read this report from ShareCast